Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia

B-cell targeted therapeutics in clinical development

(2013) Stephan Blüml et al.   ARTHRITIS RESEARCH & THERAPY

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

(2012) M. S. Topp et al.   BLOOD

Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infections

(2012) Carla Casulo et al.   Clinical Lymphoma Myeloma & Leukemia

Impact of Rituximab on Immunoglobulin Concentrations and B Cell Numbers after Cyclophosphamide Treatment in Patients with ANCA-Associated Vasculitides

(2012) Nils Venhoff et al.   PLoS One

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

(2011) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of treatment reduction for childhood acute lymphoblastic leukemia on serum immunoglobulins and antibodies against vaccine-preventable diseases

(2011) Cornelis M. van Tilburg et al.   PEDIATRIC BLOOD & CANCER

Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis

(2010) Erika Irie et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study

(2010) Marinus H.J. van Oers et al.   JOURNAL OF CLINICAL ONCOLOGY

Does rituximab aggravate pre-existing hypogammaglobulinaemia?

(2010) L. Diwakar et al.   JOURNAL OF CLINICAL PATHOLOGY

Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma

(2009) Y. L. Kasamon et al.   ANNALS OF ONCOLOGY

Profound Hypogammaglobulinemia 7 Years after Treatment for Indolent Lymphoma

(2008) Alison R. Walker et al.   CANCER INVESTIGATION

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

(2008) R. Bargou et al.   SCIENCE